AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

Search

Indivior PLC

Chiusa

841.5 -0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

825

Massimo

851.5

Metriche Chiave

By Trading Economics

Entrata

-19M

47M

Vendite

-33M

266M

P/E

Media del settore

330

56.602

EPS

0.41

Margine di Profitto

17.669

Dipendenti

1,030

EBITDA

-30M

76M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.96% upside

Dividendi

By Dow Jones

Utili prossimi

24 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

266M

1.1B

Apertura precedente

842.15

Chiusura precedente

841.5

Indivior PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2025, 20:54 UTC

Acquisizioni, Fusioni, Takeovers

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mag 2025, 20:50 UTC

Utili

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mag 2025, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mag 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mag 2025, 23:39 UTC

Discorsi di Mercato

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mag 2025, 23:08 UTC

Discorsi di Mercato

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mag 2025, 22:45 UTC

Acquisizioni, Fusioni, Takeovers

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mag 2025, 22:44 UTC

Notizie principali

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mag 2025, 22:20 UTC

Notizie principali

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q EPS 10c >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q Sales $972M >JHX

20 mag 2025, 20:52 UTC

Notizie principali

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mag 2025, 20:52 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2025, 20:52 UTC

Discorsi di Mercato

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mag 2025, 20:28 UTC

Acquisizioni, Fusioni, Takeovers

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mag 2025, 20:23 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mag 2025, 20:22 UTC

Utili

XP 1Q Adj EPS BRL2.29 >XP

20 mag 2025, 20:22 UTC

Utili

XP 1Q Rev BRL4.345B >XP

20 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mag 2025, 20:20 UTC

Notizie principali

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mag 2025, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mag 2025, 20:11 UTC

Notizie principali

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mag 2025, 20:09 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Confronto tra pari

Modifica del prezzo

Indivior PLC Previsione

Obiettivo di Prezzo

By TipRanks

19.96% in crescita

Previsioni per 12 mesi

Media 1,014.84 GBX  19.96%

Alto 1,100 GBX

Basso 969.526 GBX

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Indivior PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.